Kinomics accelarating biosensors

Deutsche Version >>
Home | Products | Literature | News | Contact | Imprint
Products
Kinomics defined beneficial, unique add-ons for affinity-based biosensors.

Multi-Step Kinetics (MSK®)

The new MSK®* methodology allows for up to 90 % of time savings in kinetics and concentration assays utilizing commercially available affinity biosensors. Mass-transport limitations and rebinding effects are clearly detected and can be considered. Superior confidence (self-consistency) of kinetics results is given by means of multiple cross-checks.

You perform a stepwise increase of the analyte concentration ("quick-motion" titration) without regeneration steps; i.e., without re-capturing the ligand in case a capture assay is applied. The MSK® software automatically evaluates the affinogram, yielding six differently constructed kinetics graphs, which permit multiple cross-checks. Since all graphs are based on straight-line equations, they can be intuitively and rapidly assessed. Additionally, an automated "traffic light" instantaneously and transparently indicates the quality of the cross-checks, and, hence, the self-consistency of the kinetics results.

Beyond saving time, you also save sample, especially in capture assays.
Since there is ideally no need for regeneration, also its tedious development is unnecessary.

  Affinogram - click to enlarge >>
click to enlarge Affinogram



* EU patent # 1 259 810 issued/published Nov 2, 2006
    US patent # 7,824,924 issued/published Nov 2, 2010

The first patent-protected method for MSK®:
· from the inventor of the method
· unlimited number of concentration changes
· contact times may be set individually for each step
· outliers can be omitted from evaluation
· quantitative detection of mass-transport limitations (if present)
· transparent kinetics results due  to multiple cross-correlation
· a simulated ideal affinogram returns the predicted kinetics without any significant error
· applicable to any assay type; extra benefits and savings  in assays difficult or
  impossible to regenerate, capture assays, or parallel interaction arrays

© Kinomics GmbH 2004-2017
Last updated: 01/22/2017
Topics
Since 12/31/2016, Kinomics GmbH is in Liquidation (i.L.). This process will be finalized at the end of 2017.